ClinicalTrials.gov
public full text
Public Domain
Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer
Objective: This study is to observe the safety and therapeutic effect of cryoablation combined with pd-1 antibody immunotherapy and anti-angiogenesis therapy in multiple primary lung cancer (MPLC) patients. Methods: In this study, 20 patients with MPLC who conform to the admission criteria are enrolled and began to receive treatment with Camrelizumab combined with Apatinib after cryoablation.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Cryoablation combined with immunotherapy: new strategies and progress in the treatment of tumors.#613443
- Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma#995651
- Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma#969602
- Percutaneous Cryoablation Peripheral Lung Cancer#1171274
- Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma#623521
Record · ID 838403
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive